» Articles » PMID: 6775673

Factor VII and Fibrinolytic Response to Deamino-8-D-argenine Vasopressin in Normal Subjects and Dissociate Response in Some Patients with Haemophilia and Von Willebrand's Disease

Overview
Journal Br J Haematol
Specialty Hematology
Date 1980 Jul 1
PMID 6775673
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Deamino-8-D-argenine vasopressin (DDAVP) was given by intravenous infusion to normal subjects, haemophiliacs and patients with von Willebrand's disease (vWd) and the factor VIII and plasminogen activator response was studied. In normal subjects and most patients with mild haemophilia and mild (intermediate) von Willebrand's disease there was an increase in plasminogen activator and all factor VIII related activities. In patients with mild vWd the prolonged bleeding time was shortened by DDAVP despite only a modest rise in factor VIII related Ristocetin cofactor activity (VIIIR:RiCoF). Sub-groups of patients have been characterized in whom atypical responses was observed. In two brothers with clinically severe haemophilia, but with 5--6 u/dl procoagulant factor VIII (VIIIC), there was an increase in VIIIC but no rise of the corresponding antigen, suggesting increased release of an antigenically abnormal poorly functioning molecule. A patient with intermediate vWd was studied in whom neither DDAVP, adrenaline infusion, nor venous occlusion resulted in an increase in either plasminogen activator or factor VIII related antigen (VIIRAg), although there was a significant increase in VIIIC. In a further patient with severe vWd, DDAVP failed to elicit any plasminogen activator or VIII response. The results obtained from these two patients suggested that in some individuals the presumed endothelial cell abnormality in vWd may be more extensive than a defect in VIIIRAg synthesis. Sub-groups of patients have been identified for whom treatment with factor VIII concentrates would be more appropriate than DDAVP prior to minor surgery.

Citing Articles

The molecular basis of memory. Part 3: tagging with "emotive" neurotransmitters.

Marx G, Gilon C Front Aging Neurosci. 2014; 6:58.

PMID: 24778616 PMC: 3985027. DOI: 10.3389/fnagi.2014.00058.


Current management of von Willebrand's disease.

Castaman G, Rodeghiero F Drugs. 1995; 50(4):602-14.

PMID: 8536549 DOI: 10.2165/00003495-199550040-00003.


Clinical experience with deamino-8-D-AGR-Vasopressin (DDAVP) in patients with Factor VIII deficiency.

Sweeney J, Crosby P, McCann S, Temperley I Ir J Med Sci. 1981; 150(8):236-9.

PMID: 6974718 DOI: 10.1007/BF02938244.


The subcutaneous administration of the vasopressin analogue 1-desamino-8-D-arginine vasopressin in patients with von Willebrand's disease and hemophilia.

Kohler M, Hellstern P, Reiter B, von Blohn G, Wenzel E Klin Wochenschr. 1984; 62(11):543-8.

PMID: 6471780 DOI: 10.1007/BF01727749.


Vascular damage and factor-VIII-related antigen in the rheumatic diseases.

Belch J, Zoma A, Richards I, McLaughlin K, Forbes C, Sturrock R Rheumatol Int. 1987; 7(3):107-11.

PMID: 3118442 DOI: 10.1007/BF00270462.